ZA200410275B - Salt of (S)-pantoprazole and its hydrates - Google Patents
Salt of (S)-pantoprazole and its hydrates Download PDFInfo
- Publication number
- ZA200410275B ZA200410275B ZA200410275A ZA200410275A ZA200410275B ZA 200410275 B ZA200410275 B ZA 200410275B ZA 200410275 A ZA200410275 A ZA 200410275A ZA 200410275 A ZA200410275 A ZA 200410275A ZA 200410275 B ZA200410275 B ZA 200410275B
- Authority
- ZA
- South Africa
- Prior art keywords
- pantoprazole
- magnesium
- pantoprazole magnesium
- medicament
- hydrates
- Prior art date
Links
- 150000004677 hydrates Chemical class 0.000 title claims description 26
- 229960005019 pantoprazole Drugs 0.000 title claims description 21
- 150000003839 salts Chemical class 0.000 title description 8
- IQPSEEYGBUAQFF-SANMLTNESA-N 6-(difluoromethoxy)-2-[(s)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-SANMLTNESA-N 0.000 claims description 76
- 239000011777 magnesium Substances 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 32
- 229910052749 magnesium Inorganic materials 0.000 claims description 27
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 19
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 230000009858 acid secretion Effects 0.000 claims description 7
- DCUGZOBNIZLALZ-UHFFFAOYSA-N magnesium;dihydrate Chemical compound O.O.[Mg] DCUGZOBNIZLALZ-UHFFFAOYSA-N 0.000 claims description 7
- 206010013710 Drug interaction Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000001055 magnesium Nutrition 0.000 description 22
- 229940091250 magnesium supplement Drugs 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 159000000003 magnesium salts Chemical class 0.000 description 13
- -1 3,4-dimethoxy-2-pyridinyl Chemical group 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 229960004048 pantoprazole sodium Drugs 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 108010079943 Pentagastrin Proteins 0.000 description 7
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 7
- 229960000444 pentagastrin Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 229920000333 poly(propyleneimine) Polymers 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000004683 dihydrates Chemical class 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 3
- RDRUTBCDIVCMMX-UHFFFAOYSA-N magnesium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC.COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC RDRUTBCDIVCMMX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PWWDEIMGEBPTJL-UHFFFAOYSA-N 1-(pyridin-2-ylmethylsulfinyl)benzimidazole Chemical class C1=NC2=CC=CC=C2N1S(=O)CC1=CC=CC=N1 PWWDEIMGEBPTJL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RYOOHIUJEJZCFT-UHFFFAOYSA-N 2-[2-(diethylamino)ethylamino]-2-phenylacetic acid 3-methylbutyl ester Chemical compound CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1 RYOOHIUJEJZCFT-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-AREMUKBSSA-N 6-(difluoromethoxy)-2-[(r)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-AREMUKBSSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229910019567 Re Re Inorganic materials 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- YNAZEDCTBGQCLV-UHFFFAOYSA-L [O-]OOOO[O-].[Mg+2] Chemical compound [O-]OOOO[O-].[Mg+2] YNAZEDCTBGQCLV-UHFFFAOYSA-L 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960005242 camylofin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 229940004894 expecta Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229960004018 magaldrate Drugs 0.000 description 1
- IPDNLDQRVVOUCT-UHFFFAOYSA-N magnesium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1,2-dihydrobenzimidazol-3-ide Chemical compound [Mg++].COc1ccnc(CS(=O)C2Nc3ccc(OC(F)F)cc3[N-]2)c1OC.COc1ccnc(CS(=O)C2Nc3ccc(OC(F)F)cc3[N-]2)c1OC IPDNLDQRVVOUCT-UHFFFAOYSA-N 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- HFTSQAKJLBPKBD-UHFFFAOYSA-N magnesium;butan-1-olate Chemical compound [Mg+2].CCCC[O-].CCCC[O-] HFTSQAKJLBPKBD-UHFFFAOYSA-N 0.000 description 1
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 1
- KRPXAHXWPZLBKL-UHFFFAOYSA-L magnesium;diphenoxide Chemical compound [Mg+2].[O-]C1=CC=CC=C1.[O-]C1=CC=CC=C1 KRPXAHXWPZLBKL-UHFFFAOYSA-L 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- SPPNVMTVMQOKSC-UHFFFAOYSA-A pentaaluminum decamagnesium hentriacontahydroxide disulfate hydrate Chemical compound O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O SPPNVMTVMQOKSC-UHFFFAOYSA-A 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- IKNCGYCHMGNBCP-UHFFFAOYSA-N propan-1-olate Chemical compound CCC[O-] IKNCGYCHMGNBCP-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- BZGIPVGCJGXQTA-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] n,n-diphenylcarbamothioate Chemical compound C=1C=CC=CC=1N(C(=O)SCCN(CC)CC)C1=CC=CC=C1 BZGIPVGCJGXQTA-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229950008375 tenatoprazole Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
SALT OF (S)-PANTOPRAZOLE AND ITS HYDRATES
Subject-matter of the Invention
The present invention relates to novel salts of the active compound (S)-pantoprazole. The novel salts can be used in the pharmaceutical industry for preparing medicaments.
Owing to their H/K*-ATPase-inhibitory action, pyridin-2-yimethylsulphinyl-1H-benzimidazoles, such as those known, for example, from EP-A-0005129, EP-A-0166287, EP-A-0174726 and EP-A-0268956 are of considerable importance in the therapy of disorders associated with an increased secretion of gastric acid.
Examples of active compounds from this group which are commercially available or in clinical develop- ment are 5-methoxy-2-[(4-methoxy-3,5-dimethyi-2-pyridiny)methyisulphinyl]-1H-benzimidazole (INN: omeprazole), (S)-5-methoxy-2-{(4-methoxy-3,5-dimethyi-2-pyridinyl)methylsulphinyl]-1H-benzimidazole (INN: esomeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyi]-1H-benzimida- zole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyisulphinyl]-1 H-benzimi- dazole (INN: lansoprazole), 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yijmethyisulphinyi}-1H-benz- imidazole (INN: rabeprazole) and 5-methoxy-2-((4-methoxy-3,5-dimethyi-2-pyridylmethyl)sulphinyl)-1H- imidazof4,5-blpyridine (INN: tenatoprazole).
The above mentioned sulphinyl derivatives which, owing to their mechanism of action, are also referred to as proton pump inhibitors or, abbreviated, as PPI, are chiral compounds.
For the first time, the international patent application W092/08716 describes a chemical process, which allows pyridin-2-yimethyisulphinyl-1H-benzimidazoles to be separated into their optical antipodes. The compounds mentioned as being prepared in an exemplary manner include, inter alia, the compounds (+)- and (-)-5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methyisulphinyl}-1H-~ benzimidazole [= (+)- and (-)}-pantoprazole]. The international patent application W092/08716 mentions that the optical antipodes of the pyridin-2-yimethylsulphinyl-1H-benzimidazoles, i.e. the (+)- and (-)- enantiomers or the (R)- and (S}-enantiomers, are useful as active compounds in medicaments for the treatment of gastrointestinal disorders. For the mode of application and the dosage of the active compounds, reference is made, inter alia, to the European patent 166 287.
The international patent applications W094/24867 and W094/25028 claim the use of the compounds (-}- and (+)-pantoprazole for treating gastric disorders in humans. Each stereoisomer is said to have medical advantages compared to the respective other stereoisomer. The descriptions also mention a number of different possible salts of the stereoisomers, and particular preference is given to the sodium salt.
In international patent application W094/27988, certain salts of (+)- and (-romeprazole and methods for their preparation are disclosed.
The international patent application W097/41114 describes a certain process for preparing magnesium salts of pyridin-2-ylmethylsulphinyl-1H-benzimidazoles. What is described in an exemplary manner is, inter alia, the preparation of the magnesium salt of racemic pantoprazole. According to the given analytical data, the salt that is prepared is racemic pantoprazole magnesium in anhydrous form.
The international patent application W000/10995 describes the dihydrate of the magnesium salt of racemic pantoprazole.
A common property of all of the abovementioned PP! is their sensitivity to acids (ultimately essential for effectiveness) which becomes apparent in their strong tendency to decompose in a neutral and in par- ticular an acidic environment, giving rise to intensely coloured decomposition products. In the past, there has been no lack of considerable efforts, in spite of the sensitivity of the PPI to acids, to obtain stable and storable oral dosage forms comprising these PPI. Such stable and storable oral dosage forms (for example tablets or capsules) are now obtainable. However, the preparation of these oral dosage forms is relatively complicated, and with respect to the packaging too, certain complicated precautions have to be taken so that the dosage forms are sufficiently stable on storage even under extreme storage conditions (for example in tropical regions at high temperatures and high atmospheric humidity). Furthermore, in the past, there has been no lack of efforts to tailor the release of the PPI in the human body in the best possible manner to the respective requirements.
Degcription of the invention
It has now been found that the sodium salt of (-)- or (S)}-pantoprazole, which is particularly preferred in the international patent application WO 94/24867, does not form a stable storage form. During various attempts to obtain a stable oral dosage form for (-)-pantoprazole, it has now been found that the magnesium salt, in particular in hydrate form, has highly surprising stability properties, making it a particularly suitable candidate for use in solid or oral dosage forms. Compared to the sodium salt of (-)- pantoprazole, the magnesium salt has considerably improved stability properties. Thus, for example, (- )-pantoprazole magnesium dihydrate is, at 70°C, completely stable for one week and shows virtually no discolouration or decomposition, whereas over the same period of time and under identical conditions, the colour of the hydrate of (-)-pantoprazole sodium changes to brown, with formation of considerable amounts of decomposition products.
Furthermore, the (-)-pantoprazole magnesium hydrate, which is the preferred subject of the invention, is a non-hygroscopic salt having a defined water content of about 4,4 9%, which corresponds to that of : the dihydrate, whereas (-)-pantoprazole sodium absorbs water depending on drying conditions and atmospheric humidity, and, correspondingly, its water content varies from 2 to 12 %. This absorption of water is reversible, so that it is difficult to adjust an exact water content. Surprisingly, not only the (-)- pantoprazole sodium, but also the (-)-pantoprazole calcium shows these poor stability properties. The water content of (-)-pantoprazole calcium varies from 4-8 % depending on drying conditions and atmospheric humidity.
Compared to the racemic pantoprazole magnesium dihydrate, the (-)-pantoprazole magnesium dihydrate has, surprisingly, better wettability, a considerably higher dissolution rate at pH 7-7,4 and, at pH 10, about tenfold better solubility.
Accordingly, the invention provides in a first aspect the magnesium salt of (-}-pantoprazole [= (S)- pantoprazole]. Preferably, the invention provides the magnesium salt (-)}-pantoprazole [= (S)- pantoprazole] hydrates, i.e. the hydrates of the compound magnesium (-)-bis{[5-(difluoromethoxy)]-2- [(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1H-benzimidazolide}. Here, particular emphasis is given to: hydrates, which - after drying under reduced pressure at 50°C - have a water content of from about 4.0 to about 6.7%, in particular from about 4.0 to about 5.5 %. Particular preference is given to the hydrate form which has a water content of from about 4.0 to about 5.0 %, in particular from about 4.2 to about 4.6 %, which corresponds to a dihydrate. (-+Pantoprazole magnesium and its hydrates can be used for the treatment and prevention of all disorders, which can be treated or prevented by using PPL. In particular, (-}-pantoprazole magnesium and its hydrates can be used for treating gastric disorders. In this context, particular mention should be made of the relatively high stability of (-)-pantoprazole magnesium in the form of its dihydrate. On storage under atmospheric conditions, the sum of by-products in (-)-pantoprazole magnesium dihydrate remains virtually constant, whereas in the case of (-)-pantoprazole sodium, under identical conditions (storage at 60-70°C) the purity (according to HPLC) decreases from 99.5 to 96-97 %. This relatively high storage stability makes (-)-pantoprazole magnesium dihydrate particularly suitable for use in medicaments.
The hydrates of (-)-pantoprazole magnesium are prepared in a manner known per se by reacting (-)- pantoprazole with a magnesium base, for example a magnesium alkoxide, or from a readily soluble (-)- pantoprazole salt (for example (-)-pantoprazole sodium) using a magnesium salt in water or in mixtures of water with polar organic solvents (for example alcohols, preferably methanol, ethanol or isopropanol, or ketones, preferably acetone).
Magnesium salts suitable for use in the process are, for example, magnesium chloride, magnesium bromide, magnesium fluoride, magnesium iodide, magnesium formate, magnesium acetate, magne-
sium propionate, magnesium gluconate or magnesium carbonate. It Is also possible to react magne- sium alkoxides (for example magnesium methoxide, magnesium ethoxide, magnesium (iso)propoxide, magnesium butoxide, magnesium hexoxide or magnesium phenoxide) in an alkoholate medium with {-)-pantoprazole or (-}-pantoprazole sodium and to crystallise the (-)-pantoprazole magnesium hydrates by addition of water. Furthermore, it is possible to recrystallise the (-)pantoprazole magnesium hydrates from, e.g., methanol/water mixtures. }
For use in solid, in particular oral, pharmaceutical formulations, the (--pantoprazole magnesium hydrate according to the invention is milled in order to obtain crystals with a particle size distribution of 90%, preferably 99 % below 100 pm.
According to the invention, “(-)}-pantoprazole” is understood to include “(-)-pantoprazole, substantially free of the (+)-enantiomer”.
The examples below illustrate the invention in more detail, without limiting it. m. p. denotes melting point, min. denotes minute(s), h denotes hour(s).
Examples 1. Magnesium {-)-bis{[5-(difluoromethoxy}l-2- imethoxy-2-pyridinyl)methylsulphinyl}-1H- benzimidazolide} dihydrate
At 20-25°C, 20.2 g (52.7 mmol) of (-)-pantoprazole {(-+[5-{difluoromethoxy)}-2-[(3,4-dimethoxy-2-pyri- dinyl)methylsulphinyl}-1H-benzimidazole} were suspended in 200 ml of purified water. A solution of (55.2 mmol) sodium hydroxide in 10 mi of water was added, and the mixture was stirred at 20-30°C for min. With addition of a filter aid (1g Hyflo-Super-Cel), the turbid solution was filtered. 6.32 g (31.2 mmol) of magnesium dichloride hexahydrate in 150 ml of water were then added drop by drop with stirring over a period of 30 min. After a further 30 min., the precipitated solid was filtered off with suction using a suction filter, stired with water (2 x 50 ml) and again filtered off with suction. Drying under reduced pressure at 50-60°C gave, in a yield of 17.36 g (80%), a hydrate of magnesium (-}- bis{[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methyisulphinyl}-1 H-benzimidazolide} having a water content of 4.5-4.7 % as a colourless to beige powder (m. p. 158-161°C, with decomposition).
Specific rotation: ap®® = -114° (¢ = 0.5, measured in methanol)
For recrystallisation, 1.88 g of the hydrate were, at 55°C, dissolved in 6 ml of methanol, and 20 ml of water were added with stirring. A colourless to beige solid crystallized out. This gave the title compound of m. p. 160-163°C (with decomposition) having a water content of 4.3-4.4%.
Alternatively, the title compound can also be prepared from organic-aqueous solvent mixtures. To this end, (-)-pantoprazole sodium, or (-~pantoprazole together with one equivalent of aqueous, for example 2N, sodium hydroxide solution, is dissolved in an organic solvent, for example warm acetone. 0.5 to 0.55 equivalents of a magnesium salt (for example magnesium chloride hexahydrate), dissolved in water, are added drop by drop, and the mixture is cooled with stirring. The precipitated solid Is filtered off, washed with the solvent mixture in question and dried at 50°C under reduced pressure until the weight remains constant. This gives the title compound as a colourless to beige powder. 2. Magnesium (-)-bis{[5-{difluoromethoxy)]-2-{(3.4-dimethoxy-2-pyridinyl)methylsulphinyf}-1 H- benzimidazolide} dihydrate
A. (-)-Pantoprazole-Na 36 g of (-)-pantoprazole were suspended in 180 ml of methyl isobutyl ketone (MIBK) and 18 ml of 2-propanol and heated to an internal temperature of 45°C. The suspension was stirred at this tempera- ture for 15 min. At 50°C, 11 g of 30% (w/w) aqueous sodium hydroxide solution were slowly added drop by drop to this suspension. A clear to slightly turbid solution resulted. This solution was stirred for a bit longer and then filtered to give a clear solution.
The clear filtrate was slowly cooled to room temperature. Between 45°C and 30°C, crystallization, which could be accelerated by seeding with (-)-pantoprazole sodium, began. The resulting suspension was stirred at an internal temperature of < 20°C for another 2 h. The suspension was then filtered, and the crystals were washed with 40 ml of MIBK.
Drying was carried out in a vacuum drying cabinet at < 50 mbar and 40-45°C. [it is also possible to dis- pense with drying and to use the moist product (having an MIBK content of 10-20 %) directly for step BJ. The white-beige crystalline product obtained after drying was hygroscopic. The water content was from 2 to 12 %. The absorption and release of water were reversible. Yield: 34 g =90 % of theory (based on anhydrous product). Specific rotation: ap™® = - 95 (¢ = 0.5, measured in methanol, sodium salt having a water content of 12%). m. p.: 145-165°C (decomposition, sodium salt having a water content of 2 %); 102-109°C (decomposition, sodium salt having a water content of 12 %).
B. (-)-Pantoprazole-Mg g of (-}-pantoprazole sodium salt (calculated anhydrous substance) were suspended in 260 ml of water. The suspension was heated to 35-40°C and stirred at 35-40°C for another 10 min. This gave a clear solution. The clear solution was cooled to 22-27°C. 14.3 g of magnesium chloride hexahydrate were dissolved in 100 m! of water, and at room temperature and with stirring, the solution was slowly added dropwise to the (-)}-pantoprazole sodium salt solution. The resulting suspension was then stirred at room temperature for another 4 h. The suspension was, under pressure, filtered through a Nutsche filter, and the product was, a little at a time, washed twice with 300 ml of water. Drying in a vacuum drying cabinet at < 50 mbar and 40-45°C gave 27.5 g (90 %) of the title compound of m. p. 160-163°C.
Water content 4.3-4.4 %; specific rotation: ap? =-129 (c= 0.5, measured in methanol).
Recrystallisation of (-)-pantoprazole-Mg
For recrystallisation, 6.0 g of the (-)-pantoprazole-Mg-dihydrate were, at 55°C, dissolved in 18 ml of methanol. After 15 min, 90 ml of water were added with stirring to the orange-brown-solution. A colour- less to beige solid crystallised out. The resulting suspension was then stirred at 20-25°C for another 1 hour. The solid was filtered off, washed with 10 ml of water and dried under vacuum for 20 hours at 50°C. The yield for the title compound was 88 % (5.26 g) with the following data:
M.P.: 161-165°C (with decomposition)
Specific rotation: ap?” =-130° (c = 0.5, measured in methanol)
XRD-Data: The X-ray powder diffraction patterns were measured on a Philips PW 1800 diffractometer at ambient temperature in the range of 3° < 2¢ < 80°. The X-ray powder diffraction patterns of (-)- pantoprazole magnesium dihydrate, are characterized by reflections with strong (2¢ about 23°), medium (2 about 6°, 12°, 14°, 17°, 19°, 22°, 24°, 25°, 30°, 33° and 35°) and small (2¢ about 13°, 16°, 26°, 28°, 33° and in the range of 36° to 62°) intensities. An exemplary X-ray powder diffraction diagram is shown below: 23untnls
ACU Yon ee et tn erm cv an ———— + — nA om tn rm = 3% em mis © om = = = YY " 3800 : ! ! ~ ! ! | 1 {i J k I | A \ f ) by Tis AoA [ IH TR A, , ) ; { LYEHY. SY Wf W A Mand TT e Fr Vm re pry a Re Re a Ee anal Es *ZThota
The X-ray powder diffraction diagram of (-}-pantoprazole magnesium dihydrate.
Commercial utility (-}-Pantoprazole magnesium and its hydrates have useful pharmacological properties, rendering them commercially utilizable. In particular, they have a pronounced inhibitory effect on the secretion of gastric acid and excellent gastrointestinal protective action in warm-blooded animals, in particular man.
Here, the compounds according to the invention are distinguished by a highly selective action, an advantageous duration of action, a particularly high bioavailability, a metabolization profile that is uniform among different individuals, the lack of significant side-effects and a wide therapeutic spectrum. in this context, “gastrointestinal protection” is to be understood as the prevention and treatment of gastrointestinal disorders, in particular gastrointestinal inflammatory disorders and lesions (such as, for example, Ulcus ventriculi, Ulcus duodeni, gastritis, irritable bowel owing to an increased production of acid or as a result of medicaments, GERD, Crohn's disease, IBD) which may be caused, for example, by microorganisms (for example Helicobacter pylori), bacterial toxins, medicaments (for example cer- tain antiphlogistics and antirheumatic drugs), chemicals (for example ethanol), gastric acid or stress.
With their excellent properties, (-}-pantoprazole magnesium and hydrates thereof are, in various models for the determination of antiulcerogenic and antisecretory properties, surprisingly clearly superior to the prior art compounds, in particular with respect to their stability and their metabolization properties. Owing to these properties, (-)-pantoprazole magnesium and hydrates thereof are highly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of gastrointestinal disorders.
Accordingly, the invention furthermore provides the use of (-)-pantoprazole magnesium and hydrates thereof for the treatment and/or prophylaxis of the abovementioned diseases.
The invention also embraces the use of (-)-pantoprazole magnesium and hydrates thereof for preparing medicaments used for the treatment and/or prophylaxis of the abovementioned diseases.
The invention also provides medicaments comprising (-)-pantoprazole magnesium and hydrates thereof.
The medicaments are prepared by processes known per se which are familiar to the person skilled in the art. As medicaments, (-)-pantoprazole magnesium hydrates are employed either as such or, preferably, in combination with suitable pharmaceutical auxiliaries or carriers in the form of tablets, coated tablets, capsules, suppositories, plasters (for example as TTS), emulsions, suspensions or solutions, where the content of active compound is advantageously from about 0.1 to about 95% and where it is possible to produce pharmaceutical dosage forms (for example flow-release forms or enteric forms) which, by the appropriate choice of auxiliaries and carriers, are tailored for the active compound and/or the desired onset of action and/or the duration of action.
The auxiliaries or carriers suitable for the desired pharmaceutical formulations are known to the person skilled in the art. In addition to solvents, gel formers, suppository bases, tabletting auxiliaries and other carriers for active compounds, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavour-masking agents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complex formers (for example cyclodextrins). (-)-Pantoprazole magnesium and hydrates thereof can be administered orally, parenterally or percu- taneously.
In human medicine, it has generally been found to be advantageous to administer (-)-pantoprazole magnesium hydrates, when given orally, in a daily dose of from about 0.1 to about 2, preferably about 0.2 to about 1.5 and in particular about 0.3 to about 1.1, mg/kg of body weight [based on (-)- pantoprazole), if appropriate in the form of a plurality of, preferably 1 to 4, individual doses, to obtain the desired result. For parenteral treatment, it is possible to use similar or (in particular when the active compounds are administered intravenously) generally lower dosages. The optimum dosage and the type of administration of the active compounds required in each case can easily be determined by the person skilled in the art.
A further aspect of the invention is thus a medicament, comprising a (-}-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of (-)-pantoprazole.
A further aspect of the invention is a medicament, comprising a (-}-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 20 to about 80 mg of (-)-pantoprazole.
A further aspect of the invention is the use of (-)-pantoprazole magnesium and hydrates thereof for treating gastrointestinal disorders.
A further aspect of the invention is the use of (-)-pantoprazole magnesium and hydrates thereof for treating gastrointestinal disorders in patients who are slow metabolizers.
A further aspect of the invention is the use of (-}-pantoprazole magnesium and hydrates thereof for treating gastrointestinal disorders in patients who have a risk of drug interactions.
A further aspect of the invention is the use of (-}-pantoprazole magnesium and hydrates thereof for treating gastrointestinal disorders in patients who need an inhibition of acid secretion for an extended period of time.
A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising a (-)-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of (-)- pantoprazole.
A further aspect of the invention Is a medicament for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising a (-)-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 20 to about 80 mg of (-)- pantoprazoie.
A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who have a risk of drug interactions, comprising a (-)-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of {(-)-pantoprazole.
A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who have a risk of drug interactions, comprising a (-)-pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 20 to about 80 mg of (-)-pantoprazole. - A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising a (-)- pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of (-)-pantoprazole.
A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising a (-)- pantoprazole magnesium hydrate together with customary auxiliaries, where the single dose comprises from about 20 to about 80 mg of (-)-pantoprazole.
If (-)-pantoprazole magnesium and hydrates thereof are to be used for treating the abovementioned di- seases, the pharmaceutical preparations may also comprise one or more pharmacologically active ingredients from other groups of medicaments. Examples that may be mentioned include tranquilizers {for example from the group of the benzodiazepines, e. g., diazepam), spasmolytic drugs (e. g., bi- etamiverine or camylofine), anticholinergic drugs (e. g., oxyphencyclimine or phencarbamide), local anesthetics (e. g., tetracaine or procaine), and optionally aiso enzymes, vitamins or amino acids.
In this context, particular emphasis is given to the combination of the compounds according to the invention with other pharmaceuticals which buffer or neutralize gastric acid or which inhibit the secre- tion of acld, such as, for example, antacids (such as, for example, magaldrate) or H, blockers (e. g., cimetidine, ranitidine), and with gastrin antagonists with the aim to enhance the main action in an additive or superadditive sense and/or to eliminate or reduce side-effects or to obtain a more rapid onset of action. Mention may also be made of the fixed or free combination with NSAIDs (such as, for example, etofenamate, diclofenac, indometacin, ibuprofen or piroxicam) for preventing the gastrointe- stinal damage caused by the NSAIDs, or with compounds, which modify gastrointestinal motility, or with compounds, which reduce the incidence of transient lower esophageal sphincter relaxation (TLOSR), or with antibacterial substances (such as, for example, cephalosporins, tetracyclins, penicillins, macrolides, nitroimidazoles or else bismuth salt) for controlling Helicobacter pylori.
Antibacterial combination partners that may be mentioned include, for example, medocillin, ampicillin, amoxicillin, cefalothin, cefoxitin, cefotaxim, imipenem, gentamycin, amicacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e. g., clarithro- mycin + metronidazole or amoxicillin + clarithromycin).
Pharmacological Investigations 1. Metabolization on human liver microsomes
I. Materials and methods
I) Human liver microsomes: Pantoprazole racemate and the (+)- and (-)-enantiomers (10 pM each) were incubated with human fiver microsomes (source: TEBU, incubation in 1 mg/ml protein, 100 mM
Tris-HCI, pH 7.4, 1 mM NADPH,). Reaction was terminated after 30 and 120 minutes by liquid nitro- gen, the parent compound was detected by HPLC (10 mM KH,PO,, pH 7.4, acetonitril gradient 20- 48 %).
I) Recombinant CYP 2C19 (source: GENTEST); incubation method as described under [) (in presence of 0.1 mg/ml protein).
Il) Recombinant CYP 3A4 (source: GENTEST); incubation method as described under 1) (in presence of 0.3 mg/ml protein).
Il. Results (-)-Pantoprazole (26 %, mean, n = 3, SD = 3, 120 min) was significantly less metabolized on human microsomes compared to the (+) enantiomer (44 %, mean , n = 3, SD = 2, 120 min) and the racemate (44 %, mean , SD = 4, 120 min), respectively. Similarly, on CYP2C19 the values were for: (-)- pantoprazole (54 %, mean, n = 3, SD = 3, 120 min); (+)-pantorazole: (64, mean, n =3, SD =5, 120 min); racemate (67 %, mean, n= 3, SD = 1, 120 min). The biotransformation on CYP3A4 was not different among the enantiomers and the racemate.
The lower biotransformation rate of (-)-pantoprazole compared to the (+) enantiomer lets expecta lower biotransformation in vivo as well with the result of higher plasma levels of (-)-pantoprazole.
Clinically, this may translate into an even lower risk for drug interactions for (-)-pantoprazole. 2. Inhibition of acid output in the Ghosh-Schild rat after i.v. administration.
I. Introduction
Pyridin-2-ylmethylsulphinyl-1H-benzimidazoles are chiral compounds. The two enantiomers, which exist for each pyridin-2-yimethylsulphinyl-1H-benzimidazole, are prodrugs that require acid-catalyzed activation into a sulfenamide, which is achiral and for both enantiomers identical. The achiral sulfenamide then reacts covalently with cysteines of the gastric proton pump to block it. Hence, in pharmacodynamic terms, the two enantiomers should display identical potencies and efficacies, provided they are in vivo metabolized at the same rate. This was assumed in case of pantoprazole based on rat data that have shown almost identical percentage inhibitions by the two enantiomers of the sodium salt (see Kromer, W., Scand. J. Gastroenterol. 2001, 36, suppl. 234: 3-9, fig. 5). Such previous experiments covered 3.5 hours following intravenous drug administration and have now been repeated with the two enantiomers of the magnesium salt of pantoprazole. In addition, the effects of the two enantiomers of the magnesium salt of pantoprazole have now been determined in the time interval between 3 and 7.5 hours following i.v. administration of 1 pmol/kg of the magnesium salts of the two enantiomers. il. Materials and methods.
Female Sprague Dawley CD rats (190 - 210 g body weight) were anaesthetised with 1.5 g/kg i.m. of urethane, in 5 mifkg physiologic saline. The trachea was intubated and both, the left external jugular vein (for drug administration) and left femoral vein (for pentagastrin infusion) were cannulated. An esophagus/cardia-cannula (diameter: 1.7 mm) was inserted transorally, and a pylorus-cannula (diameter: 2.6 mm) was inserted through the duodenum, and both were secured with a ligature. The pyloric catheter was led through the right abdominal wall. Body temperature was maintained at 37.0 + 0.2°C by means of infrared radiation and electric cushion (automatic infinite control via rectal temperature probe). After thorough flushing (about 50 - 100 ml), the stomach was continuously perfused with 0.5 ml/min of physiologic saline (37°C). In the effluate, collected at 15 min intervals, the pH as well as the acid output were determined, the latter by titration to pH 7 with freshly prepared 0.01
N NaOH.
Gastric secretion was stimulated by a continuous intravenous infusion (left femoral vein) of 1 pg/kg x min pentagastrin (in 1.6 ml/h physiologic saline) starting after determination of two basal values of acid secretion, i.e., 30 min after commencement of stomach perfusion. See horizontal bars in figs. 1 and 2 for pentagastrin-infusion. 1 pmol/kg of (-)-pantoprazole-Mg or (+)-pantoprazole-Mg was administered intravenously in a volume of 1 ml/kg body weight as an 30 sec i.v. injection. Controls received the corresponding amount of physiologic saline. Note that 1 umol pantoprazole-Mg is equivalent to 2 pmol of the free acid of pantoprazole.
Experiment 1: Drug administration1 hour after commencement of pentagastrin stimulation (see Figure 1).
Experiment 2: Drug administration 3 hours prior to commencement of pentagastrin stimulation (see
Figure 2).
Ill. Results
Figure 1 of Experiment 1 clearly shows that the two enantiomers of pantoprazole-Mg are equieffective in blocking acid output during the first 3.5 hours following drug administration. 40 gE ® w 2 TAY = 4 i {oper = o-pr-1 l 2 >» I 1 1 ! 2 i a) " BE z 1 5 4 AS 4
I 20 i i
E | \ 8 a 15 ly 2 3
F
J s ve | a on = - 3
FS D Ceo 8-ui TWEE 0 0 30 60 90 120 150 180 210 240 270 300
TIME {MIN
Figure 1: Acid inhibition by intravenous pantoprazole-Mg-enantiomeres. Drug administration 1 hour after commencement of pentagastrin stimulation. {o) 1 pmol/kg iv (-) ~pantoprazole-Mg; (¢) 1 pmol/kg iv (+) - pantoprazole-Mg; {o) Control
In Experiment 2, where the drug was administered 3 hours prior to commencement of acid stimulation by pentagastrin, and acid output was measured over the following 4.5 hours, it was found, surprisingly, that the (-)-enantiomer was significantly superior to the (+)-enantiomer in inhibiting acid secretion (Figure 2).
a 15 i JA : ri N26] ’ = 5-H g HH] = i fA) ® Sp: hr by 20 . \ a 15 | 48
Oo [ 3D < y 3
[1] $ < 2 $9 Po5 5 5.5000
Blood collection: 2 54 8 16 60 120 18p f 240 300 420 min
Drug [B-£3 , v 3 [+] 30 80 80 120 150 180 210 240 270 300 330 360 390 420 450 [iM MIN
Figure 2: Influence of intravenous pantoprazole-Mg-enantiomeres.
Drug administration 3 hours before commencement of pentagastrin stimulation. (oc) 1 pmol/kg Iv (-) —pantoprazole-Mg; (e) 1 pmol/kg iv (+) - pantoprazole-Mg; (o) Control
The (-)}-enantiomer is significantly more effective than the (+)-enantiomer in the time interval between 3 and 7.5 hours after drug administration. It is important to note that this difference in favour of the (-)- enantiomer is maintained and still significant even 7.5 hours after i.v. drug administration.
This unexpected finding could be explained for example, if the preferential and favourable binding of pantoprazole to cysteine 822 of the proton pump was mainly due to the binding of its (-)-enantiomer,
This could be therapeutically exploited by administering the (-)-enantiomer of pantoprazole in order to achieve a longer duration of action, compared to the racemate or to the other PPIs that do not bind to cysteine 822 at all (Shin, J.M., and Sachs, G., Gastroenterology 2002, 123: 1588-1597).
Claims (1)
- Claims1. (-)}-Pantoprazole magnesium [(S)-pantoprazole magnesium) and its hydrates.2. (-)-Pantoprazole magnesium [(S)-pantoprazole magnesium] hydrates.3. A (-}-pantoprazole magnesium hydrate according to claim 2, having a water content of from 4.0 to8.7 %.4. A (-}pantoprazole magnesium hydrate according to claim 2, having a water content of from 4.0 to5.5%.8. A(-)}-pantoprazole magnesium hydrate according to claim 2, having a water content of from 4.0 to5.0 %.8. A (-}pantoprazole magnesium hydrate according to claim 2, having a water content of from 4.2 to4.6 %.7. A (-}pantoprazole magnesium hydrate according to claim 2, which Is (-)-pantoprazole magnesium dihydrate.8. A (-)}pantoprazole magnesium hydrate according to any of claims 2 to 7 with a particle size distribution of 98 % below 100 pm.9. A (-}pantoprazole magnesium hydrate according to any of daims 2 to 7 with X-ray powder diffraction patterns which are characterized by reflections with strong (24 about 23°), medium (2$ about 6°, 12°, 14°, 17°, 19°, 22°, 24°, 25°, 30°, 33" and 35°) and small (24 about 13°, 16°, 26°, 28°, 33° ard in the range of 36° to 62°) intensities.10. Medicament, comprising a compound according to any of Claims 1 to 9 together with customary41. Medicament, comprising a compound according to any of Claims 1 to 9 together with customary awndiiaries, where the single dose comprises from about 10 to about 100 mg of {-}pantoprazofe.12. Use of (-)-pantoprazole magnesium and its hydrates in the manufacture of a medicament for treating gastrointestinal disorders.13. Use of (-)-pantoprazole magnesium and its hydrates in the manufacture of a medicament for treating gastrointestinal disorders in patients who are slow metabolizers. AMENDED SHEET14. Use of (-)-pantoprazole magnesium and its hydrates in the manufacture of a medicament for treating gastrointestinal disorders in patients who have a risk of drug interactions.15. Use of (-)-pantoprazole magnesium and its hydrates in the manufacture of a medicament for treating gastrointestinal disorders in patients who need an inhibition of acid secretion for an extended period of time.16. Medicament for treating gastrointestinal disorders for use In patients who are slow metabolizers, comprising a compound according to any of Claims 1 to 7 together with customary auxiliaries, where the single dose comprises from about 10 ta about 100 mg of (-)}-pantoprazole.17. Medicament for treating gastrointastinal disorders for use in patients who have a risk for drug inter- actions, comprising a compound according to any of Claims 1 to 7 together with customary auxilla- ries, where the single dose comprises from about 10 to about 100 mg of (-)-pantoprazole.18. Medicament for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising a compound according to any of Claims 1 to 7 together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of (-)}-pantoprazole.19. Compounds according to claim 1, substantially as herein described and exemplified.20. Medicament according to any one of claims 10,11,16,17 or 18, substantially as herein described and exemplified.21. Use according to any one of claims 12-15, substantially as herein described and exemplified. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002134617 DE10234617B4 (en) | 2002-07-29 | 2002-07-29 | New salt of (S) -pantoprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200410275B true ZA200410275B (en) | 2006-07-26 |
Family
ID=30128511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200410275A ZA200410275B (en) | 2002-07-29 | 2004-12-21 | Salt of (S)-pantoprazole and its hydrates |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE10234617B4 (en) |
ZA (1) | ZA200410275B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005070426A1 (en) * | 2004-01-27 | 2005-08-04 | Altana Pharma Ag | Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE508669C2 (en) * | 1996-04-26 | 1998-10-26 | Astra Ab | New procedure |
DE19843413C1 (en) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | New salt form of pantoprazole |
-
2002
- 2002-07-29 DE DE2002134617 patent/DE10234617B4/en not_active Expired - Fee Related
-
2004
- 2004-12-21 ZA ZA200410275A patent/ZA200410275B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE10234617B4 (en) | 2013-04-04 |
DE10234617A1 (en) | 2004-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050155A2 (en) | Salt of (s)-pantoprazole and its hydrates | |
JP5289951B2 (en) | Isotopically substituted pantoprazole | |
IL211335A (en) | Pyrrole compounds | |
MXPA01001758A (en) | Novel salt form of pantoprazole. | |
CA2489470A1 (en) | Prodrug and process for producing the same | |
EP1651217B1 (en) | Alkaline salts of proton pump inhibitors | |
KR20070045194A (en) | S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor | |
US20080234326A1 (en) | Novel Salts of Pantoprazole and (S) - Pantoprazole | |
ZA200410275B (en) | Salt of (S)-pantoprazole and its hydrates | |
NZ538429A (en) | Magnesium salt of (S)-pantoprazole and its hydrates | |
JP2007534723A (en) | Dialkoxy-imidazopyridine derivatives | |
WO2005011691A1 (en) | Improved binding of pantoprazole to the proton pump | |
WO2005011593A2 (en) | Improved binding of pantoprazole to the acid pump | |
WO2005012289A1 (en) | Novel salt of (r) - pantoprazole | |
US20070244115A1 (en) | Amino-Halogen-Imidazopyridines as Proton Pump Inhibitors | |
ZA200510178B (en) | Alkaline salts of proton pump inhibitors |